The global vitamin market shows mixed signals as Q4 approaches. Vitamin E prices are under renewed pressure despite strong supply, while Vitamin A remains steady at historically low levels. Vitamin D3 continues to see wide price gaps, and D-Calpan sentiment stays cautious amid bearish trends. Meanwhile, Vitamin B3 is showing early signs of recovery, with some suppliers raising prices.
In partnership with Feed Additive Prices
Vitamin E 50%
Despite experiencing a brief period of minimal price declines and a relatively stable market, recent trends indicate a renewed decrease in prices. Although vitamin E manufacturers are hesitant to reduce their prices, there is an ample supply available through various channels and a willingness to lower prices to maintain market presence. At present, contracts for the fourth quarter are still only partially finalised.
Vitamin A 1000
The current stability in prices seems to be maintained, as there are hardly any signs of further decreases. Suppliers are holding back on additional price cuts, with some even ceasing to provide products entirely, leaving traders to be the primary source of any available discounts. At present, prices remain notably low. There are still some movements observed for Q4 contracts and even slightly beyond, though with caution.
Vitamin D3 500
The market remains largely unchanged from previous weeks, with a Chinese manufacturer re-entering with substantially elevated pricing that does not align with current transaction prices. Despite this, the market has shown little response, as more competitively priced materials are available, indicating a clearer reflection of real transaction values. Consequently, the price differential remains significant, and Q4 is only conservatively contracted.
D-Calpan
Despite a gradual stabilisation in prices this week, the overall market sentiment remains predominantly bearish, reflecting a cautious outlook. While some activity can be observed within the market, most buyers continue to exercise a high degree of wait-and-see, showing reluctance to engage in purchases even at currently low price points. Q4 is not fully contracted yet.
Vitamin B3
The market is beginning to exhibit promising signs of stability as a number of suppliers are opting to suspend their offerings or increase prices after experiencing a significant period of low price levels. As a result, many end-users are either finalising or contemplating securing their supply volumes for the fourth quarter and even the first quarter of the upcoming year.
